Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Zinc in GNAO1 Associated Disorders
NCT06412653Phase 2Completed
- Sponsor
- Children's University Hospital Cologne
- Start
- Aug 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zinc acetate in GNAO1-associated disorder (GNAO1), sponsored by Children's University Hospital Cologne. Primary endpoints: Feasibility of daily treatment with oral zinc at 6 months, Safety assessed by regular evaluation of side effects at 7 months and 1 more. Started Aug 2024; status: completed.
02
Drugs
zinc acetate
03
Conditions
GNAO1-associated disorder (GNAO1)
Beyond the preview
Go deeper on NCT06412653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06412653.